Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 482
Filtrar
1.
Int J Mol Sci ; 25(18)2024 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-39337515

RESUMEN

Diabetic cardiomyopathy is a major etiological factor in heart failure in diabetic patients, characterized by mitochondrial oxidative metabolism dysfunction, myocardial fibrosis, and marked glycogen elevation. The aim of the present study is to evaluate the effect of endurance training and prebiotic xylooligosaccharide (XOS) on the activity of key oxidative enzymes, myocardial collagen, and glycogen distribution as well as some serum biochemical risk markers in streptozotocin-induced type 1 diabetic rats. Male Wistar rats (n = 36) were divided into four diabetic groups (n = 9): sedentary diabetic rats on a normal diet (SDN), trained diabetic rats on a normal diet (TDN), trained diabetic rats on a normal diet with an XOS supplement (TD-XOS), and sedentary diabetic rats with an XOS supplement (SD-XOS). The results show that aerobic training managed to increase the enzyme activity of respiratory Complex I and II and the lactate dehydrogenase in the cardiomyocytes of the diabetic rats. Furthermore, the combination of exercise and XOS significantly decreased the collagen and glycogen content. No significant effects on blood pressure, heart rate or markers of inflammation were detected. These results demonstrate the beneficial effects of exercise, alone or in combination with XOS, on the cardiac mitochondrial enzymology and histopathology of diabetic rats.


Asunto(s)
Diabetes Mellitus Experimental , Diabetes Mellitus Tipo 1 , Entrenamiento Aeróbico , Glucuronatos , Oligosacáridos , Condicionamiento Físico Animal , Prebióticos , Ratas Wistar , Animales , Ratas , Masculino , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/complicaciones , Glucuronatos/farmacología , Prebióticos/administración & dosificación , Entrenamiento Aeróbico/métodos , Glucógeno/metabolismo , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/metabolismo , Enfermedades Cardiovasculares/prevención & control , Cardiomiopatías Diabéticas/metabolismo , Cardiomiopatías Diabéticas/etiología
2.
J Anim Sci ; 1022024 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-39155504

RESUMEN

The beneficial effects of xylo-oligosaccharides (XOS) on the intestine have been widely reported, including anti-inflammation, antioxidant, maintenance of intestinal epithelial barrier, and treatment of intestinal injury. However, the specific mechanism of XOS in mitigating intestinal injury in weaned piglets remains unclear. Therefore, this study aimed to explore the specific mechanism of XOS in mitigating intestinal injury. The study is a complete randomized design with 24 weaned piglets in a 2 × 2 factorial arrangement that includes diet treatments (basal diet vs. 0.02% XOS) and immunological challenge [saline vs. lipopolysaccharide (LPS)]. All piglets were fed a basal diet or a XOS diet for 21 d. On day 22, all piglets received an injection of LPS or saline. In this study, dietary XOS increased jejunal villus height, reduced crypt depth and oxidative stress, and enhanced the gene and protein expression of Claudin-1, Occludin, and zonula occludens 1 (P < 0.05). The piglets fed the XOS diet had lower serum Diamine oxidase activity and d-lactic acid content (P < 0.05). In addition, dietary XOS regulates endoplasmic reticulum (ER)-mitochondria system function and the expression of key molecules, including mitochondrial dynamics dysfunction [mitofusin (Mfn)-1, optic atrophy 1, fission 1, and dynamin-related protein 1], ER stress [activating transcription factor 4 (ATF4), ATF6, C/EBP-homologous protein, eukaryotic initiation factor 2α, glucose-regulated protein (GRP) 78, GRP94, and protein kinase R-like ER kinase] and the mitochondria-associated ER membranes (MAM) disorders (Mfn2, GRP75, and voltage-dependent anion channel 1) (P < 0.05). Therefore, the findings to indicate that dietary XOS is effective against LPS-induced jejunal injury may be attributed to its ability to alleviate mitochondrial dynamics dysfunction, ER stress, and MAM disorders.


Intestinal injury can have a range of negative impacts on weaned piglets. Xylo-oligosaccharides are known for their beneficial effects on the gut, including anti-inflammatory and antioxidant properties, and also help maintain the intestinal epithelial barrier and reduce intestinal injury. However, the exact mechanism by which xylo-oligosaccharides reduce intestinal injury in piglets remains unclear. The endoplasmic reticulum­mitochondrial system, endoplasmic reticulum and mitochondria, along with the mitochondria-associated endoplasmic reticulum membranes that connect them, plays a crucial role in mediating intestinal injury in piglets. Therefore, this study aimed to investigate whether xylo-oligosaccharides affect intestinal injury in piglets through the endoplasmic reticulum, mitochondria, and the mitochondria-associated endoplasmic reticulum membranes. The results of this study indicate that xylo-oligosaccharides mitigate intestinal injury in piglets by alleviating endoplasmic reticulum stress, mitochondrial dynamics dysfunction, and mitochondria-related endoplasmic reticulum membrane disorders, providing a theoretical basis for the treatment of intestinal injury with xylo-oligosaccharides.


Asunto(s)
Alimentación Animal , Dieta , Retículo Endoplásmico , Lipopolisacáridos , Oligosacáridos , Animales , Oligosacáridos/farmacología , Oligosacáridos/administración & dosificación , Porcinos , Dieta/veterinaria , Alimentación Animal/análisis , Retículo Endoplásmico/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Intestinos/efectos de los fármacos , Suplementos Dietéticos , Mucosa Intestinal/efectos de los fármacos , Glucuronatos/farmacología , Glucuronatos/administración & dosificación , Masculino , Enfermedades de los Porcinos/inducido químicamente , Enfermedades de los Porcinos/prevención & control , Distribución Aleatoria , Estrés Oxidativo/efectos de los fármacos
3.
Biomed Pharmacother ; 179: 117340, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39191025

RESUMEN

Scutellarin (Scu), a flavonoid from herbal Erigeron breviscapus (Vaniot) Hand-Mazz, exerts neuroprotective effects against cerebral ischemia. However, whether the effects of Scu are related to mitochondrial protection needs further investigation. In this study, we aimed to clarify the mechanisms of Scu against HT22 cells injury caused by oxygen-glucose deprivation and reperfusion (OGD/R). Our results proved that Scu significantly reduced the overload of intracellular reactive oxygen species (cellar ROS) and mitochondria reactive oxygen species (mito-ROS), ameliorating oxidative stress damage. TUNEL positive rate, Caspase-3 activity, and Cytochrome c (Cyto-c) expression remarkably decreased following Scu treatment. Meanwhile, Scu could maintain mitochondrial morphology and reverse ultrastructure changes. And mitochondrial membrane potential (MMP), oxygen consumption rate (OCR), adenosine triphosphate (ATP) production and Na+/K+-ATPase activity were obviously promoted. Additionally, Scu was found to stimulate mitophagy level by increasing the expression of LC3, Beclin1, PINK1 and Parkin proteins, as well as promoting the degradation of p62. More importantly, the regulatory effects of Scu on mito-ROS, MMP, ATP, Na+/K+-ATPase, cell viability and lactate dehydrogenase (LDH) were markedly limited by Mdivi-1 (a mitophagy inhibitor). Of note, the inhibitor also reversed Scu-mediated apoptosis suppression, evidenced by the diminished apoptosis rate, the down-regulated expression activities of Cyto-c, Bax and cleaved Caspase-3, as well as the elevated level of Bcl-2 protein. Collectively, Scu could improve mitochondrial dysfunction and inhibit apoptosis by stimulating mitophagy, thereby attenuating OGD/R-induced HT22 cells injury.


Asunto(s)
Apigenina , Apoptosis , Glucosa , Glucuronatos , Mitocondrias , Mitofagia , Apigenina/farmacología , Glucuronatos/farmacología , Mitofagia/efectos de los fármacos , Apoptosis/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Animales , Ratones , Línea Celular , Glucosa/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Estrés Oxidativo/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/metabolismo , Daño por Reperfusión/patología , Oxígeno/metabolismo , Supervivencia Celular/efectos de los fármacos
4.
Int J Biol Macromol ; 277(Pt 2): 134346, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39094883

RESUMEN

To date, although the high-carbohydrate (HC) feed has been extensively adopted in the aquaculture industry, its effects on the intestinal function and development of aquatic animals still remain unclear. In addition, the corresponding nutritional intervention is still barely reported. This study aimed to evaluate the influence of xylooligosaccharides (XOS) on the intestinal health of Megalobrama amblycephala subjected to a HC feeding. Fish (average weight: 44.55 ± 0.15 g) were randomly offered 3 diets, including a control one (29 % carbohydrate), a HC one (41 % carbohydrate), and a XOS supplemented one (HC + 1.0 % XOS, HCX) respectively for 12 weeks. The HC feeding caused morphological abnormalities of intestine, an increased intestinal permeability, and the intestinal immunosuppression, all of which were markedly reversed by XOS administration. In addition, compared with the HC group, HCX feeding remarkably promoted the intestinal activities of digestive and brush border enzymes, and the expressions of cell proliferation-related proteins (Wnt10b and Cyclin D1). The 16s rDNA sequencing also revealed that XOS administration increased the abundance of beneficial bacteria, and decreased that of pathogenic ones. In conclusion, dietary supplementation of XOS improved the intestinal histomorphology, barrier function, cell proliferation and bacterial communities of carbohydrate-overloaded fish Megalobrama amblycephala.


Asunto(s)
Carpas , Microbioma Gastrointestinal , Glucuronatos , Intestinos , Oligosacáridos , Animales , Microbioma Gastrointestinal/efectos de los fármacos , Oligosacáridos/farmacología , Glucuronatos/farmacología , Carpas/microbiología , Carpas/crecimiento & desarrollo , Intestinos/efectos de los fármacos , Intestinos/patología , Intestinos/microbiología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Alimentación Animal , Carbohidratos de la Dieta/farmacología , Carbohidratos de la Dieta/efectos adversos , Suplementos Dietéticos
5.
Sci Rep ; 14(1): 17481, 2024 07 30.
Artículo en Inglés | MEDLINE | ID: mdl-39080323

RESUMEN

Carbimazole has disadvantages on different body organs, especially the thyroid gland and, rarely, the adrenal glands. Most studies have not suggested any solution or medication for ameliorating the noxious effects of drugs on the glands. Our study focused on the production of xylooligosaccharide (XOS), which, when coadministered with carbimazole, relieves the toxic effects of the drug on the adrenal glands. In addition to accelerating the regeneration of adrenal gland cells, XOS significantly decreases the oxidative stress caused by obesity. This XOS produced by Aspergillus terreus xylanase was covalently immobilized using microbial Scleroglucan gel beads, which improved the immobilization yield, efficiency, and operational stability. Over a wide pH range (6-7.5), the covalent immobilization of xylanase on scleroglucan increased xylanase activity compared to that of its free form. Additionally, the reaction temperature was increased to 65 °C. However, the immobilized enzyme demonstrated superior thermal stability, sustaining 80.22% of its original activity at 60 °C for 120 min. Additionally, the full activity of the immobilized enzyme was sustained after 12 consecutive cycles, and the activity reached 78.33% after 18 cycles. After 41 days of storage at 4 °C, the immobilized enzyme was still active at approximately 98%. The immobilized enzyme has the capability to produce xylo-oligosaccharides (XOSs). Subsequently, these XOSs can be coadministered alongside carbimazole to mitigate the adverse effects of the drug on the adrenal glands. In addition to accelerating the regeneration of adrenal gland cells, XOS significantly decreases the oxidative stress caused by obesity.


Asunto(s)
Glándulas Suprarrenales , Aspergillus , Carbimazol , Enzimas Inmovilizadas , Oligosacáridos , Aspergillus/efectos de los fármacos , Oligosacáridos/farmacología , Oligosacáridos/química , Enzimas Inmovilizadas/metabolismo , Enzimas Inmovilizadas/química , Glándulas Suprarrenales/efectos de los fármacos , Glándulas Suprarrenales/metabolismo , Animales , Glucuronatos/farmacología , Estrés Oxidativo/efectos de los fármacos , Endo-1,4-beta Xilanasas/metabolismo , Masculino , Ratas , Obesidad/tratamiento farmacológico
6.
FASEB J ; 38(13): e23769, 2024 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-38958951

RESUMEN

Renal ischemia-reperfusion injury (IRI) is an integral process in renal transplantation, which results in compromised graft survival. Macrophages play an important role in both the early inflammatory period and late fibrotic period in response to IRI. In this study, we investigated whether scutellarin (SCU) could protect against renal IRI by regulating macrophage polarization. Mice were given SCU (5-50 mg/kg) by gavage 1 h earlier, followed by a unilateral renal IRI. Renal function and pathological injury were assessed 24 h after reperfusion. The results showed that administration of 50 mg/kg SCU significantly improved renal function and renal pathology in IRI mice. In addition, SCU alleviated IRI-induced apoptosis. Meanwhile, it reduced macrophage infiltration and inhibited pro-inflammatory macrophage polarization. Moreover, in RAW 264.7 cells and primary bone marrow-derived macrophages (BMDMs) exposed to SCU, we found that 150 µM SCU inhibited these cells to polarize to an inflammatory phenotype induced by lipopolysaccharide (LPS) and interferon-γ (IFN-γ). However, SCU has no influence on anti-inflammatory macrophage polarization in vivo and in vitro induced by in interleukin-4 (IL-4). Finally, we explored the effect of SCU on the activation of the mitogen-activated protein kinase (MAPK) pathway both in vivo and in vitro. We found that SCU suppressed the activation of the MAPK pathway, including the extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and p38. Our results demonstrated that SCU protects the kidney against IRI by inhibiting macrophage infiltration and polarization toward pro-inflammatory phenotype via the MAPK pathway, suggesting that SCU may be therapeutically important in treatment of IRI.


Asunto(s)
Apigenina , Glucuronatos , Sistema de Señalización de MAP Quinasas , Macrófagos , Daño por Reperfusión , Animales , Masculino , Ratones , Apigenina/farmacología , Apoptosis/efectos de los fármacos , Glucuronatos/farmacología , Glucuronatos/uso terapéutico , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/prevención & control , Inflamación/patología , Riñón/metabolismo , Riñón/efectos de los fármacos , Riñón/patología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Ratones Endogámicos C57BL , Células RAW 264.7 , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/metabolismo
7.
Int Immunopharmacol ; 139: 112710, 2024 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-39029229

RESUMEN

PANoptosis is manifested with simultaneous activation of biomarkers for both pyroptotic, apoptotic and necroptotic signaling via the molecular platform PANoptosome and it is involved in pathologies of various inflammatory diseases including hemophagocytic lymphohistiocytosis (HLH). Scutellarin is a flavonoid isolated from herbal Erigeron breviscapus (Vant.) Hand.-Mazz. and has been shown to possess multiple pharmacological effects, but it is unknown whether scutellarin has any effects on PANoptosis and related inflammatory diseases. In this study, we found that scutellarin inhibited cell death in bone marrow-derived macrophages (BMDMs) and J774A.1 cells treated with TGF-ß-activated kinase 1 (TAK1) inhibitor 5Z-7-oxozeaenol (OXO) plus lipopolysaccharide (LPS), which has been commonly used to induce PANoptosis. Western blotting showed that scutellarin dose-dependently inhibited the activation biomarkers for pyroptotic (Caspase-1p10 and GSDMD-NT), apoptotic (cleaved Casp3/8/9 and GSDME-NT), and necroptotic (phosphorylated MLKL) signaling. The inhibitory effect of scutellarin was unaffected by NLRP3 or Caspase-1 deletion. Interestingly, scutellarin blocked the assembly of PANoptosome that encompasses ASC, RIPK3, Caspase-8 and ZBP1, suggesting its action on upstream signaling. Consistent with this, scutellarin inhibited mitochondrial damage and mitochondrial reactive oxygen species (mtROS) generation in cells treated with OXO+LPS. Further, mito-TEMPO that can scavenge mtROS significantly inhibited OXO+LPS-induced PANoptotic cell death. In line with the in vitro results, scutellarin markedly alleviated systemic inflammation, multiple organ injury, and activation of PANoptotic biomarkers in mice with HLH. Collectively, our data suggest that scutellarin can inhibit PANoptosis by suppressing mitochondrial damage and mtROS generation and thereby mitigating multiple organ injury in mice with inflammatory disorders.


Asunto(s)
Apigenina , Glucuronatos , Lipopolisacáridos , Ratones Endogámicos C57BL , Mitocondrias , Especies Reactivas de Oxígeno , Apigenina/farmacología , Apigenina/uso terapéutico , Glucuronatos/farmacología , Glucuronatos/uso terapéutico , Animales , Especies Reactivas de Oxígeno/metabolismo , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Ratones , Línea Celular , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Macrófagos/inmunología , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Necroptosis/efectos de los fármacos , Masculino , Quinasas Quinasa Quinasa PAM/metabolismo , Inflamación/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Zearalenona/administración & dosificación , Lactonas , Resorcinoles
8.
Sci Rep ; 14(1): 13430, 2024 06 11.
Artículo en Inglés | MEDLINE | ID: mdl-38862696

RESUMEN

Previous studies have shown that scutellarin inhibits the excessive activation of microglia, reduces neuronal apoptosis, and exerts neuroprotective effects. However, whether scutellarin regulates activated microglia-mediated neuronal apoptosis and its mechanisms remains unclear. This study aimed to investigate whether scutellarin can attenuate PC12 cell apoptosis induced by activated microglia via the JAK2/STAT3 signalling pathway. Microglia were cultured in oxygen-glucose deprivation (OGD) medium, which acted as a conditioning medium (CM) to activate PC12 cells, to investigate the expression of apoptosis and JAK2/STAT3 signalling-related proteins. We observed that PC12 cells apoptosis in CM was significantly increased, the expression and fluorescence intensity of the pro-apoptotic protein Bax and apoptosis-related protein cleaved caspase-3 were increased, and expression of the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2) was decreased. Phosphorylation levels and fluorescence intensity of the JAK2/STAT3 signalling pathway-related proteins JAK2 and STAT3 decreased. After treatment with scutellarin, PC12 cells apoptosis as well as cleaved caspase-3 and Bax protein expression and fluorescence intensity decreased. The expression and fluorescence intensity of Bcl-2, phosphorylated JAK2, and STAT3 increased. AG490, a specific inhibitor of the JAK2/STAT3 signalling pathway, was used. Our findings suggest that AG490 attenuates the effects of scutellarin. Our study revealed that scutellarin inhibited OGD-activated microglia-mediated PC12 cells apoptosis which was regulated via the JAK2/STAT3 signalling pathway.


Asunto(s)
Apigenina , Apoptosis , Glucuronatos , Janus Quinasa 2 , Microglía , Factor de Transcripción STAT3 , Transducción de Señal , Animales , Apigenina/farmacología , Factor de Transcripción STAT3/metabolismo , Janus Quinasa 2/metabolismo , Glucuronatos/farmacología , Células PC12 , Apoptosis/efectos de los fármacos , Microglía/efectos de los fármacos , Microglía/metabolismo , Transducción de Señal/efectos de los fármacos , Ratas , Ratones , Caspasa 3/metabolismo , Glucosa/metabolismo , Fármacos Neuroprotectores/farmacología , Fosforilación/efectos de los fármacos , Proteína X Asociada a bcl-2/metabolismo , Tirfostinos/farmacología
9.
Int J Biol Macromol ; 271(Pt 2): 132575, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38788863

RESUMEN

Rice husks are rich in xylan, which can be hydrolyzed by xylanase to form xylooligosaccharides (XOS). XOS are a functional oligosaccharide such as improving gut microbiota and antioxidant properties. In this study, the structure and functional characteristics of XOS were studied. The optimal xylanase hydrolysis conditions through response surface methodology (RSM) were: xylanase dosage of 3000 U/g, hydrolysis time of 3 h, hydrolysis temperature of 50 °C. Under this condition, the yield of XOS was 150.9 mg/g. The TG-DTG curve showed that XOS began to decompose at around 200 °C. When the concentration of XOS reached 1.0 g/L, the clearance rate of DPPH reached 65.76 %, and the scavenging rate of OH reached 62.10 %, while the clearance rate of ABTS free radicals reached 97.70 %, which was equivalent to the clearance rate of VC. XOS had a proliferative effect on four probiotics: Lactobacillus plantarum, Lactobacillus brucelli, Lactobacillus acidophilus, and Lactobacillus rhamnosus. However, the further experiments are needed to explore the improvement effect of XOS on human gut microbiota, laying a foundation for the effective utilization of XOS. XOS have a wide range of sources, low price, and broad development prospects. The reasonable utilization of XOS can bring greater economic benefits.


Asunto(s)
Antioxidantes , Glucuronatos , Oligosacáridos , Oryza , Probióticos , Oligosacáridos/farmacología , Oligosacáridos/química , Oryza/química , Glucuronatos/farmacología , Glucuronatos/química , Antioxidantes/farmacología , Antioxidantes/química , Hidrólisis , Endo-1,4-beta Xilanasas/metabolismo , Lactobacillus
10.
Mar Drugs ; 22(5)2024 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-38786584

RESUMEN

Parkinson's disease (PD) is a prevalent neurodegenerative disorder, and accumulating evidence suggests a link between dysbiosis of the gut microbiota and the onset and progression of PD. In our previous investigations, we discovered that intraperitoneal administration of glucuronomannan oligosaccharides (GMn) derived from Saccharina japonica exhibited neuroprotective effects in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. However, the complicated preparation process, difficulties in isolation, and remarkably low yield have constrained further exploration of GMn. In this study, we optimized the degradation conditions in the preparation process of GMn through orthogonal experiments. Subsequently, an MPTP-induced PD model was established, followed by oral administration of GMn. Through a stepwise optimization, we successfully increased the yield of GMn, separated from crude fucoidan, from 1~2/10,000 to 4~8/1000 and indicated the effects on the amelioration of MPTP-induced motor deficits, preservation of dopamine neurons, and elevation in striatal neurotransmitter levels. Importantly, GMn mitigated gut microbiota dysbiosis induced by MPTP in mice. In particular, GM2 significantly reduced the levels of Akkermansia, Verrucomicrobiota, and Lactobacillus, while promoting the abundance of Roseburia and Prevotella compared to the model group. These findings suggest that GM2 can potentially suppress PD by modulating the gut microbiota, providing a foundation for the development of a novel and effective anti-PD marine drug.


Asunto(s)
Modelos Animales de Enfermedad , Microbioma Gastrointestinal , Ratones Endogámicos C57BL , Oligosacáridos , Animales , Microbioma Gastrointestinal/efectos de los fármacos , Ratones , Oligosacáridos/farmacología , Masculino , Fármacos Neuroprotectores/farmacología , Disbiosis/tratamiento farmacológico , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/farmacología , Neuronas Dopaminérgicas/efectos de los fármacos , Enfermedad de Parkinson/tratamiento farmacológico , Manosa/farmacología , Manosa/química , Manosa/análogos & derivados , Glucuronatos/farmacología
11.
Int J Biol Macromol ; 269(Pt 1): 132134, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38719013

RESUMEN

Stimulus-responsive nanomaterials, particularly with targeting capabilities, have garnered significant attention in the cancer therapy. However, the biological safety of these innovative materials in vivo remains unknown, posing a hurdle to their clinical application. Here, a pH/H2O2 dual-responsive and targeting nano carrier system (NCS) was developed using core shell structure of Fe3O4 mesoporous silicon (MSN@Fe3O4) as main body, scutellarin (SCU) as antitumor drug and polymer cyclodextrin (PCD) as molecular switch (denoted as PCD@SCU@MSN@Fe3O4, abbreviated as NCS). The NCS, with an average particle size of 100 nm, displayed exceptional SCU loading capacity, a result of its uniform radial channel structure. The in vitro investigation under condition of pH and H2O2 indicated that NCS performed excellent pH/H2O2-triggered SCU release behavior. The NCS displayed a higher cytotoxicity against tumor cells (Huh7 and HCT116) due to its pH/H2O2 dual-triggered responsiveness, while the PCD@MSN@Fe3O4 demonstrated lower cytotoxicity for both Huh7 and HCT116 cells. In vivo therapeutic evaluation of NCS indicates significant inhibition of tumor growth in mouse subcutaneous tumor models, with no apparent side-effects detected. The NCS not only enhances the bioavailability of SCU, but also utilizes magnetic targeting technology to deliver SCU accurately to tumor sites. These findings underscore the substantial clinical application potential of NCS.


Asunto(s)
Apigenina , Ciclodextrinas , Portadores de Fármacos , Glucuronatos , Peróxido de Hidrógeno , Silicio , Animales , Humanos , Ciclodextrinas/química , Ratones , Peróxido de Hidrógeno/química , Apigenina/química , Apigenina/farmacología , Portadores de Fármacos/química , Concentración de Iones de Hidrógeno , Glucuronatos/química , Glucuronatos/farmacología , Silicio/química , Porosidad , Antineoplásicos/farmacología , Antineoplásicos/química , Línea Celular Tumoral , Ensayos Antitumor por Modelo de Xenoinjerto , Liberación de Fármacos , Neoplasias/tratamiento farmacológico , Nanopartículas/química , Celulosa
12.
J Asian Nat Prod Res ; 26(8): 867-882, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38594834

RESUMEN

Phenolics produced during xylooligosaccharide production might inhibit xylanases and enhance the antioxidant and antimicrobial activities of XOS. The effects of phenolic compounds on xylanases may depend on the type and concentration of the compound, the plant biomass used, and the enzyme used. Understanding the effects of phenolic compounds on xylanases and their impact on XOS is critical for developing viable bioconversion of lignocellulosic biomass to XOS. Understanding the complex relationship between phenolic compounds and xylanases can lead to the development of strategies that improve the efficiency and cost-effectiveness of XOS manufacturing processes and optimise enzyme performance.


Asunto(s)
Glucuronatos , Oligosacáridos , Fenoles , Prebióticos , Oligosacáridos/química , Oligosacáridos/farmacología , Glucuronatos/farmacología , Glucuronatos/química , Fenoles/química , Fenoles/farmacología , Estructura Molecular , Antioxidantes/farmacología , Antioxidantes/química , Endo-1,4-beta Xilanasas/metabolismo
13.
Chem Biodivers ; 21(6): e202400258, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38581076

RESUMEN

We presented a strategy utilizing 2D NMR-based metabolomic analysis of crude extracts, categorized by different pharmacological activities, to rapidly identify the primary bioactive components of TCM. It was applied to identify the potential bioactive components from Scutellaria crude extracts that exhibit anti-non-small cell lung cancer (anti-NSCLC) activity. Four Scutellaria species were chosen as the study subjects because of their close phylogenetic relationship, but their crude extracts exhibit significantly different anti-NSCLC activity. Cell proliferation assay was used to assess the anti-NSCLC activity of four species of Scutellaria. 1H-13C HSQC spectra were acquired for the chemical profiling of these crude extracts. Based on the pharmacological classification (PCA, OPLS-DA and univariate hypothesis test) were performed to identify the bioactive constituents in Scutellaria associated with the anti-NSCLC activity. As a result, three compounds, baicalein, wogonin and scutellarin were identified as bioactive compounds. The anti-NSCLC activity of the three potential active compounds were further confirmed via cell proliferation assay. The mechanism of the anti-NSCLC activity by these active constituents was further explored via flow cytometry and western blot analyses. This study demonstrated 2D NMR-based metabolomic analysis of pharmacologically classified crude extracts to be an efficient approach to the identification of active components of herbal medicine.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Proliferación Celular , Espectroscopía de Resonancia Magnética , Metabolómica , Extractos Vegetales , Scutellaria , Scutellaria/química , Humanos , Proliferación Celular/efectos de los fármacos , Extractos Vegetales/farmacología , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Apigenina/farmacología , Apigenina/química , Apigenina/aislamiento & purificación , Apigenina/análisis , Flavanonas/farmacología , Flavanonas/química , Flavanonas/aislamiento & purificación , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Glucuronatos/farmacología , Glucuronatos/aislamiento & purificación , Glucuronatos/química , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales
14.
Adv Biol (Weinh) ; 8(7): e2400123, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38684459

RESUMEN

Scutellarin is an herbal agent which can exert anti-neuroinflammatory effects in activated microglia. However, it remains uncertain if it can inhibit microglia-mediated neuroinflammation by regulating miRNAs. This study sought to elucidate the upstream regulatory mechanisms by endogenous microRNAs and its target gene in activated microglia in lipopolysaccharide (LPS)-induced BV-2 microglia. Results show that scutellarin suppressed the expression of tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), and inducible nitric oxide synthase (iNOS) significantly in LPS-stimulated BV-2 microglia. As with the results of miRNAs function classification in vitro, the expression levels of mir-7036a-5p are upregulated in LPS-activated BV-2 microglia, but are downregulated by scutellarin. Rescue experiments indicated that mir-7036a-5p is a pro-inflammatory factor in activated BV-2 microglia. mir-7036a-5p agomir promoted the expression of phosphorylated tau proteins (p-tau), protein kinase C gamma type (PRKCG), extracellular regulated protein kinases (ERK1/2), but the is reversed by mir-7036a-5p antagomir in vitro. It is shown here that mir-7036a-5p is involved in microglia-mediated inflammation in LPS-induced BV-2 microglia. More important is the novel finding that scutellarin mitigated microglia inflammation by down-regulating the mir-7036a-5p/MAPT/PRKCG/ERK signaling pathway.


Asunto(s)
Apigenina , Glucuronatos , Lipopolisacáridos , MicroARNs , Microglía , Apigenina/farmacología , Microglía/efectos de los fármacos , Microglía/metabolismo , Glucuronatos/farmacología , Lipopolisacáridos/farmacología , MicroARNs/metabolismo , MicroARNs/genética , Animales , Ratones , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Línea Celular , Proteína Quinasa C/metabolismo
15.
J Nutr Biochem ; 129: 109640, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38583497

RESUMEN

Midlife overweight and obesity are risk factors of cognitive decline and Alzheimer' s disease (AD) in late life. In addition to increasing risk of obesity and cognitive dysfunction, diets rich in fats also contributes to an imbalance of gut microbiota. Xylo-oligosaccharides (XOS) are a kind of prebiotic with several biological advantages, and can selectively promote the growth of beneficial microorganisms in the gut. To explore whether XOS can alleviate cognitive decline induced by high-fat diet (HFD) through improving gut microbiota composition, mice were fed with normal control or 60% HFD for 9 weeks to induce obesity. After that, mice were supplemented with XOS (30 g or 60 g/kg-diet) or without, respectively, for 12 weeks. The results showed that XOS inhibited weight gain, decreased epidydimal fat weight, and improved fasting blood sugar and blood lipids in mice. Additionally, XOS elevated spatial learning and memory function, decreased amyloid plaques accumulation, increased brain-derived neurotrophic factor levels, and improved neuroinflammation status in hippocampus. Changes in glycerolipids metabolism-associated lipid compounds caused by HFD in hippocampus were reversed after XOS intervention. On the other hand, after XOS intervention, increase in immune-mediated bacteria, Faecalibacterium was observed. In conclusion, XOS improved gut dysbiosis and ameliorated spatial learning and memory dysfunction caused by HFD by decreasing cognitive decline-associated biomarkers and changing lipid composition in hippocampus.


Asunto(s)
Dieta Alta en Grasa , Microbioma Gastrointestinal , Ratones Endogámicos C57BL , Oligosacáridos , Prebióticos , Animales , Microbioma Gastrointestinal/efectos de los fármacos , Dieta Alta en Grasa/efectos adversos , Oligosacáridos/farmacología , Oligosacáridos/administración & dosificación , Masculino , Ratones , Hipocampo/metabolismo , Hipocampo/efectos de los fármacos , Obesidad/metabolismo , Obesidad/microbiología , Glucuronatos/farmacología , Encéfalo/metabolismo , Encéfalo/efectos de los fármacos , Lípidos/sangre , Disfunción Cognitiva/prevención & control , Disbiosis , Metabolismo de los Lípidos/efectos de los fármacos
16.
J Anim Physiol Anim Nutr (Berl) ; 108(4): 1059-1071, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38500315

RESUMEN

The primary aim of this study was to examine the impact of xylooligosaccharide (XOS) in rice protein concentrate (RPC) based diets on the growth performance, body composition, digestive enzymes, intestinal morphology and blood biochemistry of Labeo rohita fingerlings. Four different XOS levels (0%, 0.5%, 1% and 2%) were used at each RPC (75% and 100%) level. Twenty-five fish per tank with an average initial weight of 25 ± 0.05 g were randomly assigned (Randomised complete block design) to each of the 8 groups in triplicate aquaria (36 × 16 × 12″) and then fed with respective diets @ 3% body weight for 90 days. The results showed significant improvements in growth performance, such as increased weight gain %, specific growth rate, and protein efficiency ratio and improved feed conversion ratio in 1% XOS supplemented diet at 75% RPC. A significant decrease in serum alkaline phosphatase activity (ALP) and plasma melanodialdehyde (MDA) were observed at 1% XOS level in 75% RPC based diets, respectively. Meanwhile, the lowest total cholesterol and highest lysozyme activity were observed in 1% XOS supplemented diet at 75% RPC levels. Moreover, the serum (alanine aminotransferase and aspartate transaminase) and plasma (superoxide dismutase, triglyceride, high density and low density lipoprotein) activities showed nonsignificant effects among the treatments. Furthermore, the digestive enzymes (protease & lipase) and intestinal morphology were significantly influenced at 1% XOS in the 75% RPC-based diet. Polynomial regression analysis showed that 1.25% XOS is the optimum requirement for the growth of rohu fingerlings when fed at 75% RPC based diets. Overall, it was concluded that the 75% RPC diet was efficiently replaced by fishmeal along with 1% XOS addition in L. rohita fingerlings without any negative effect on growth performance and intestinal health.


Asunto(s)
Alimentación Animal , Fenómenos Fisiológicos Nutricionales de los Animales , Cyprinidae , Dieta , Suplementos Dietéticos , Glucuronatos , Oligosacáridos , Oryza , Animales , Oligosacáridos/farmacología , Oligosacáridos/administración & dosificación , Alimentación Animal/análisis , Dieta/veterinaria , Glucuronatos/administración & dosificación , Glucuronatos/farmacología , Cyprinidae/crecimiento & desarrollo
17.
Phytomedicine ; 128: 155418, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38518647

RESUMEN

BACKGROUND: Scutellaria barbata D. Don (SB), commonly known as Ban Zhi Lian and firstly documented by Shigong Chen, is a dried whole plant that has been studied for its therapeutic effects on breast cancer, colon cancer, and prostate cancer. Among its various compounds, scutellarin (SCU) has been demonstrated with anti-tumor effects. PURPOSE: This study aimed to evaluate the effects of SB water extract (SBW) and scutellarin on breast cancer stem cells (BCSCs), and to investigate their potential therapeutic effects on breast tumors in mice. METHODS: BCSCs were enriched from human breast cancer cells (MDA-MB-231 and MDA-MB-361) and their characteristics were analyzed. The effects of varying concentrations of SBW and scutellarin on cell viability, proliferation, self-renewal, and migration abilities were studied, along with the underlying mechanisms. The in vivo anti-tumor effects of scutellarin were further evaluated in SCID/NOD mice. Firstly, mice were inoculated with naïve BCSCs and subjected to treatment with scutellarin or vehicle. Secondly, BCSCs were pre-treated with scutellarin or vehicle prior to inoculation into mice. RESULTS: The derived BCSCs expressed CD44, CD133 and ALDH1, but not CD24, indicating that BCSCs have been successfully induced from both MDA-MB-231 and MDA-MB-361 cells. Both SBW and scutellarin reduced the viability, proliferation, sphere and colony formation, and migration of BCSCs. In mice with tumors derived from naïve BCSCs, scutellarin significantly reduced tumor growth, expression of proliferative (Ki67) and stem cell markers (CD44), and lung metastasis. In addition, pre-treatment with scutellarin also slowed tumor growth. Western blot results suggested the involvement of Wnt/ß-catenin, NF-κB, and PTEN/Akt/mTOR signaling pathways underlying the inhibitory effects of scutellarin. CONCLUSION: Our study demonstrated for the first time that both SB water extract and scutellarin could reduce the proliferation and migration of BCSCs in vitro. Scutellarin was shown to possess novel inhibitory activities in BCSCs progression. These findings suggest that Scutellaria barbata water extract, in particular, scutellarin, may have potential to be further developed as an adjuvant therapy for reducing breast cancer recurrence.


Asunto(s)
Apigenina , Neoplasias de la Mama , Proliferación Celular , Glucuronatos , Ratones Endogámicos NOD , Células Madre Neoplásicas , Scutellaria , Animales , Apigenina/farmacología , Scutellaria/química , Glucuronatos/farmacología , Células Madre Neoplásicas/efectos de los fármacos , Humanos , Femenino , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ratones SCID , Antineoplásicos Fitogénicos/farmacología , Ratones , Extractos Vegetales/farmacología , Movimiento Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto , Receptores de Hialuranos/metabolismo
18.
Inflammation ; 47(3): 853-873, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38168709

RESUMEN

Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), inflammation, and remodeling. Epithelial-mesenchymal transition (EMT) is an essential player in these alterations. Scutellarin is isolated from Erigeron breviscapus. Its vascular relaxative, myocardial protective, and anti-inflammatory effects have been well established. This study was designed to detect the biological roles of scutellarin in asthma and its related mechanisms. The asthma-like conditions were induced by ovalbumin challenges. The airway resistance and dynamic compliance were recorded as the results of AHR. Bronchoalveolar lavage fluid (BALF) was collected and processed for differential cell counting. Hematoxylin and eosin staining, periodic acid-Schiff staining, and Masson staining were conducted to examine histopathological changes. The levels of asthma-related cytokines were measured by enzyme-linked immunosorbent assay. For in vitro analysis, the 16HBE cells were stimulated with 10 ng/mL transforming growth beta-1 (TGF-ß1). Cell migration was estimated by Transwell assays and wound healing assays. E-cadherin, N-cadherin, and α-smooth muscle actin (α-SMA) were analyzed by western blotting, real-time quantitative polymerase chain reaction, immunofluorescence staining, and immunohistochemistry staining. The underlying mechanisms of the mitogen-activated protein kinase (MAPK) and Smad pathways were investigated by western blotting. In an ovalbumin-induced asthmatic mouse model, scutellarin suppressed inflammation and inflammatory cell infiltration into the lungs and attenuated AHR and airway remodeling. Additionally, scutellarin inhibited airway EMT (upregulated E-cadherin level and downregulated N-cadherin and α-SMA) in ovalbumin-challenged asthmatic mice. For in vitro analysis, scutellarin prevented the TGF-ß1-induced migration and EMT in 16HBE cells. Mechanistically, scutellarin inhibits the phosphorylation of Smad2, Smad3, ERK, JNK, and p38 in vitro and in vivo. In conclusion, scutellarin can inactivate the Smad/MAPK pathways to suppress the TGF-ß1-stimulated epithelial fibrosis and EMT and relieve airway inflammation and remodeling in asthma. This study provides a potential therapeutic strategy for asthma.


Asunto(s)
Remodelación de las Vías Aéreas (Respiratorias) , Apigenina , Asma , Glucuronatos , Ovalbúmina , Proteína Smad2 , Proteína smad3 , Apigenina/farmacología , Apigenina/uso terapéutico , Remodelación de las Vías Aéreas (Respiratorias)/efectos de los fármacos , Animales , Ratones , Glucuronatos/farmacología , Glucuronatos/uso terapéutico , Ovalbúmina/toxicidad , Humanos , Asma/tratamiento farmacológico , Asma/inducido químicamente , Asma/metabolismo , Asma/patología , Proteína smad3/metabolismo , Proteína Smad2/metabolismo , Transducción de Señal/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Fibrosis/tratamiento farmacológico , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Línea Celular , Bronquios/patología , Bronquios/efectos de los fármacos , Bronquios/metabolismo , Ratones Endogámicos BALB C , Transición Epitelial-Mesenquimal/efectos de los fármacos , Fenotipo
19.
Food Funct ; 14(19): 8734-8746, 2023 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-37694718

RESUMEN

This study aimed to optimize the structure and efficacy of xylooligosaccharides (XOSs) from corn cobs in constipated mice. Structural analysis revealed that XOSs from corn cobs were composed of ß-Xyl-(1 →4)-[ß-Xyl-(1→4)]n-α/ß-Xyl (n = 0-5) without any other substituents. XOS administration significantly reduced the defecation time, increased the gastrointestinal transit rate, restored the gastrointestinal neurotransmitter imbalance, protected against oxidative stress, and reversed constipation-induced colonic inflammation. Fecal metabolite and microbiota analysis showed that XOS supplementation significantly increased short chain fatty acid (SCFA) levels and improved the gut microbial environment. These findings highlighted the potential of XOSs from corn cobs as an active ingredient for functional foods or as a therapeutic agent in constipation therapy.


Asunto(s)
Estreñimiento , Microbioma Gastrointestinal , Glucuronatos , Loperamida , Oligosacáridos , Animales , Ratones , Estreñimiento/inducido químicamente , Estreñimiento/tratamiento farmacológico , Loperamida/efectos adversos , Zea mays , Glucuronatos/farmacología , Oligosacáridos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...